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Sub-Saharan Africa holds 90% of the HIV-infected children worldwide and most of them are 
infected through vertical transmission. The elimination of mother-to-child transmission of 
HIV in this region can be achieved through complementing prophylaxis regimens with 
effective service delivery.  The latter should involve reaching all those at risk and optimizing 
adherence through adequate and routine follow-up. A study set out to assess the 
effectiveness of preventing mother-to-child transmission (PMTCT) programs in four African 
countries including South Africa using the simple nevirapine-based PMTCT regimen, found 
that prophylaxis coverage for the PMTCT of HIV was on average poor, at only 50% among 
HIV-exposed infants during 2007-2008. Incomplete HIV testing in pregnancy accounted for 
46% of missed opportunities for PMTCT intervention. In addition, discrepancies were found 
between data from cord-blood samples, which are the gold standard measure of ingestion of 
the prophylaxis by mothers and routinely collected data on the provision of prophylaxis at 
antenatal clinics. Clinic records overestimated adherence to prophylaxis which could mislead 
decisions about service delivery. Adherence to the simple nevirapine regimen, data and 
service quality should be investigated in order to identify needs for strengthening the 
effectiveness of WHO Option B guidelines which are being rolled out in resource-poor 
settings.  
This project set out to assess the extent of clinic-level PMTCT prophylaxis coverage in the 
resource-limited setting of the Free State province. Adherence to treatment as well as 
accuracy of clinic records so as to inform better service implementation were measured. A 
total of 1572 mother-infant pairs were included in a cross-sectional survey carried out in 
rural antenatal and delivery services from two health districts between 2007 and 2008. HIV 
testing and nevirapine prophylaxis data were collected by nurses and compared to 
anonymously linked cord-blood tests which confirmed true HIV status and ingestion of 
nevirapine. Logistic regression was used to assess variables from the clinic surveillance data: 
age, gravidity, mode of delivery, timing of HIV testing and number of antenatal visits during 
pregnancy, as potential predictors of adherence to nevirapine. 
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The Kappa statistic revealed a disagreement of 10% in HIV test results and 20% in nevirapine 
intake between clinic records and cord-blood. The clinic records under-estimated maternal 
HIV prevalence by 9% (22% records versus 31% cord-blood) in mothers aged between 12 and 
43 years. Also, cord-blood surveillance revealed that 19.4% of the HIV positive women 
recorded to have been offered nevirapine during labor, did not actually ingest it.  The more 
frequently a woman sought antenatal care during pregnancy, the more likely she was to 
ingest nevirapine. Women who had at least 4 antenatal visits were 4.5 times more likely to 
adhere than women who attended services only once.  
Even though this is the simplest regimen for preventing vertical HIV transmission, 
compliance to the entire antenatal cascade during pregnancy is important in improving 
adherence to therapy and preventing missed opportunities for intervention. Inaccurate 
collection of routine clinic data negatively impacts on routinely reported data outcomes. 
Major improvements need to be undertaken both at the service provider and user levels in 






















At least 90% of HIV-infected children live in sub-Saharan Africa.(1) In Africa, an estimated 3% 
of children under the age of five die due to HIV/AIDS acquired through vertical transmission, 
and in some African countries this is as high as 28%.(2) Preventing paediatric HIV infection 
will contribute to eliminating HIV and create an AIDS-free society in the future. The 
elimination of mother-to-child transmission (MTCT) of HIV in Africa can only be achieved 
through complimenting prophylactic regimens with effective service delivery.  The latter 
should involve reaching all those at risk and optimizing adherence through adequate and 
routine follow-up.(3-5) The PMTCT (prevention of mother-to-child transmission of HIV) 
Effectiveness in Africa: Research and Linkages to care (PEARL) Study set out to assess the 
effectiveness of PMTCT programs in African countries. It surveyed four African countries 
(including South Africa) and found that prophylactic coverage for PMTCT services was on 
average poor, at only 50% among HIV-exposed infants during the 2007-to-2008 period.(6)  
The South African data were sampled from the Western Cape and Free State provinces. A 
subsequent detailed assessment of the data from the Western Cape Province revealed that 
incomplete testing in pregnancy accounted for 46% of missed opportunities for PMTCT 
intervention.(7) In addition, discrepancies were found between data from cord-blood 
samples, which are the gold standard measure of ingestion of the prophylaxis by mothers 
and routinely collected data on the provision of prophylaxis at antenatal clinics.(7)  There 
were differences in 2.8% of HIV test results where clinics recorded HIV-positive outcomes 
that tested negative in the corresponding cord-blood samples. Also, clinic records 
overestimated adherence to prophylaxis which could mislead decisions about service 
delivery. The Western Cape Province is one region with the best access to ARVS at antenatal 
services in South Africa (8;9) yet these results show that there is poor linkage between the 
availability of treatment and effective service delivery. Unlike the Western Cape, the rural 
area of the Free State province is poorly serviced with some patients waiting more than a 
month to receive treatment(10) and therefore adherence to treatment and the accuracy of 
data from PMTCT services should be investigated, in order to assess the quality of services 
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and identify needs in order to complement the effectiveness of the Option B regimen which 
is currently underway*. This project set out to assess PMTCT coverage at antenatal services 
in resource-limited settings of the Free State, adherence to treatment as well as accuracy of 




The current guidelines for PMTCT programmes set out by the WHO in 2010 aim to 
significantly reduce vertical transmission of HIV mainly in low income settings.(11) Routine 
PMTCT data collected during the past three years show that the prevalence of paediatric HIV 
exposure among infants in South Africa is as high as 32%.(9;12) Despite broader coverage of 
the recommended prophylactic regimens, HIV vertical transmission at 6 weeks postpartum 
remained at 3.5% in 2010(9) while it had been successfully eliminated in many developed 
countries.(11)  Global targets have been set at eliminating paediatric HIV by 2015 through 
incorporating PMTCT of HIV programmes into the existing antenatal and mother-infant 
health services.(11) Use of fixed-dose combination antiretroviral therapy (ART) instead of 
AZT and single-dose nevirapine in pregnancy irrespective of CD4 count levels or clinical stage 
of disease is also being widely promoted(13) to reduce the transmission rate to less than 5% 
by 2015.(14) However, the level of acceptance and adherence to the simpler single dose 
nevirapine regimen (15) needs to be known in order to have insight on how achievable 
combination ART initiation will be in pregnant women.  Guidelines on the measurement of 
the effectiveness of PMTCT programmes at the population/national level have recently been 
suggested by the WHO.(16) These measures assess the level of success and challenges faced 
by PMTCT programmes and assess the feasibility of using triple therapy to achieve better 
outcomes.  
 
The PEARL study assessed PMTCT services across four African countries, Cameroon, Cote 
d’Ivoire, South Africa and Zambia and revealed that coverage of single-dose nevirapine was 
poor, with only half of the HIV-exposed infants being protected.(6) Lack of early routine HIV 
testing and repeat testing at 32-36 weeks also contributes to missed opportunities for  
*Further to the completion of this mini-thesis protocol (2013), the South African Department of Health 
announced in July, 2014, the national implementation of Option B+ from January 2015. 
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preventing paediatric transmission.(15;17;18) Analyses of local African PMTCT programmes 
prior to 2010 that used cord-blood tests for both HIV testing and for the presence of 
nevirapine, have shown that data from routine clinical records were inaccurate and that the 
assumption that all drugs dispensed to patients were actually ingested was not 
valid.(7;19;20)  
 
Although the WHO 2010 PMTCT guidelines recommend early testing and initiation of 
prophylaxis with repeat testing at 32-36 weeks for those who initially test 
negative(15;17;18), this may not occur if the health system is not functioning optimally.(21) 
Furthermore, the most recent South African guidelines recommend daily triple therapy for 
all HIV-positive pregnant women until cessation of breastfeeding (if mother does not need to 
continue with therapy for her own health), irrespective of clinical stage of disease and CD4 
count levels.(22) In both urban and rural settings the uptake of and adherence to single-dose 
regimen is poor, and the implementation of the recently proposed triple therapy for every 
HIV-positive woman will be an even greater challenge. The pre-2010 status of the PMTCT 
services in the Western Cape Province were reported in 2012 (7) and this study will assess 
the status of less well-resourced settings in the Free State Province.  As the guidelines are 




The aim of this study will be to assess PMTCT coverage and identify discrepancies in 
routinely collected data at facilities and data from a cord-blood survey in the Free State 
Province. 
The objectives will be: 
(i) To assess coverage for HIV testing and PMTCT prophylaxis at antenatal services  
(ii) To assess adherence to nevirapine prophylaxis and identify factors influencing it 
(iii) To identify discrepancies between data routinely recorded by service providers on 
the provision of HIV testing, the test results and coverage of PMTCT prophylaxis 







1.4.1 Data summary 
This is a cross-sectional survey of clinic records and cord-blood surveillance data from the 
Free State Province of South Africa (2007-2008).  The data were collected as part of the 
PEARL study.(6) The data comprises of 1679 women who delivered at one of ten clinics.  A 
total of 107 (6.4%) of these women did not attend antenatal services prior to delivery and 
will not be included in our analyses.  
1.4.1.1 Definitions 
Effectiveness (of a regimen): The degree to which prophylaxis or therapy prevent 
transmission of HIV from mother to child 
Adherence to nevirapine: presence of nevirapine in the cord-blood sample 
(confirming ingestion) where clinic records indicate that the drug was dispensed to 
the woman during pregnancy. 
Coverage (for HIV testing and treatment): the proportion of pregnant women 
attending antenatal facilities who are tested for HIV and the proportion of HIV-
positive women who are offered therapy/prophylaxis.   
 
1.4.2 Variable distributions 
The main outcome variable is adherence to nevirapine. Five potential determinants of 
adherence to nevirapine will be investigated (Table 1.4.2).  
Table 1.4.2: List of variables to be assessed as potential determinants of adherence 
Variable  Variable type : unit of measure 
Age Continuous : years 
Gravidity Ordinal : current number of children 
Mode of delivery Binary : coding for ‘vaginal’ or ‘caesarean’ 
First HIV test done before or during current 
pregnancy 
Binary : coding for ‘Before’ or ‘During’ 





1.4.3 Analyses to be carried out 
Three main analyses will be carried out to achieve the aims for the project. 
(1) The HIV testing coverage and level of adherence to prophylaxis.  
(2) Identification of factors associated with adherence to nevirapine. Variables which will 
be assessed in a logistic regression approach are listed in Table 1 and include age of 
the pregnant woman, gravidity and number of ANC visits. Some of these factors, 
including mode of delivery will be tested for possibility of effect modification and 
confounding, for example age and gravidity may be strongly correlated. 
(3) Differences and agreement between clinic records and cord-blood results will be 
assessed. The main comparisons will be on HIV test results and ingestion of 
prophylaxis. The last time-point for HIV test before delivery will be considered where 
a HIV-negative record coincides with a positive cord-blood result so as to consider the 
possibility of late sero-conversion.  
 
1.4.4 Statistical Tests  
The outcome variable is binary (i.e., the presence or absence of nevirapine in cord-blood) 
and hence logistic regression will be used in the identification of influential factors. Table 2 
gives a list of proposed statistical tests for each of the analyses objectives. 
Table 1.4.4: Proposed statistical analyses 
Analysis objective Proposed specific test 
1. Adherence and Coverage  - Proportions 
2. Identifying individual variables that influence 
adherence 
- logistic regression for each 
variable separately 
3. Check for co-variable influences such as confounding 
and interaction to further refine associations and 
obtain final list of predictor variables for adherence 
- logistic regression with stepwise 
variable addition assessing AIC 
and likelihood functions of the 
models  
4. Comparison of clinic surveillance records and cord-
blood results 







This project is part of a larger study to assess effectiveness of PMTCT programmes across 
African countries. It was conducted between 2007 and 2009 (see attached ethical approval: 
REC Ref 038/2007) in APPENDIX A. Women were informed about this study during their 
antenatal visits at the clinic by study staff and through posters in the waiting rooms. When 
data were collected from the clinics, they were not linked to any personal identifiers. Study 
numbers were used instead of folder numbers or names in order to protect participants’ 
privacy and confidentiality. Therefore the participant could not be traced using the records 
collected for analyses. There were no anticipated risks for patients associated with this study 
since the drawing of cord-blood occurred after the birth, using the discarded placenta, and 
analyses were done outside the clinics on the unlinked data. A copy of the clinic surveillance 
form which was used to collect individual, anonymous data from the clinic records is 
attached in APPENDIX B. The results of this analysis will benefit the respective region and the 
country at large in improved implementation of future PMTCT programmes. This will be 
achieved through informing the Department of Health about our findings. Also, the outcome 
of the analyses will be published in a peer-reviewed journal for the benefit of other 
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2. CHAPTER 2: Literature Review 
 
Nearly all HIV infections in children are through vertical transmission either during 
pregnancy, labour, child birth or breastfeeding. In the absence of prophylaxis, the risk of 
transmission  ranges between 15% and 40% depending on feeding mode [1]. The infant 
exposure rates to HIV infection are highest in the Sub-Saharan Africa where nearly a third of 
global adult infections are found as well as the highest under-5 child mortality rates [2,3]. 
The World Health Organization (WHO) published evidence-based guidelines in 2010 to be 
adopted by affected countries in order to reduce mother-to-child transmission (MTCT) of HIV 
worldwide by half before 2015 [4]. However, better progress was easily achievable in 
developed countries while the low-to-middle income countries struggled [5]. In South Africa,  
guidelines have been set and are being implemented towards achieving improved PMTCT 
targets by 2015, such reducing vertical transmission rate to less than 2% among 6 week- old 
HIV-exposed infants [6].  
 
 2.1 Global health efforts to reduce MTCT at the time of the new millennium 
 
The WHO first published evidence-based recommendations for use of antiretrovirals (ARVs) 
in PMTCT in 2000. Although HIV incidence was higher in Africa, treatment was not easily 
affordable and thus little progress took place in terms of implementing the guidelines. In 
2006, revised guidelines were released specifically aimed at resource-limited settings such as 
most parts of Africa with the aim of achieving free HIV testing, counselling and treatment for 
all pregnant women by 2010 [7]. In 2010, the integration of PMTCT programs into routine 
antenatal services was an important recommendation which made access and delivery 
easier [4].  This was to enable routine testing for HIV and monitoring of CD4 count levels in 
particular, so as to ensure timely initiation of treatment and prophylaxis among pregnant 
women. Evidence from numerous follow-up studies has shown that delaying the initiation of 
treatment or starting treatment when CD4 count levels are decreasing below 350cells/µl 






2.1.1 WHO guidelines for PMTCT between 2006 and 2013 
In the 2006 WHO guidelines for lowering mother-to-child transmission (MTCT) of HIV in resource-
limited settings, a CD4 count less than 200cells/mm3 or clinical disease stage 4 were highlighted as 
the critical points at which treatment should be initiated [7]. A CD4 count of 350cells/mm3 was 
considered if the clinical disease was above stage 2 [7]. These guidelines were complex and difficult 
to implement, given the human and laboratory resources required for frequent monitoring [9].   
However, waiting for a CD4 count less than 200 to initiate therapy is risky and may be too late to 
ensure recovery [10]. Therefore, in 2010, the WHO published revised guidelines aimed to achieve a 
vertical transmission rate of less than 5% for 35% exposure and below 2% for a 25% exposure in low-
to-middle income countries [11]. In an attempt to streamline guidelines and their implementation, 
the 2010 guidelines recommended ‘Option A’ regimen for mothers in need of HIV treatment for their 
own health, i.e., with CD4 count of less than 350cells/mm3, to continue with daily life-long 
antiretroviral  therapy (ART) throughout antepartum and intrapartum phases of pregnancy [4, 11].  
 
Alternatively, when the CD4 count was above 350cells/mm3 PMTCT prophylaxis was recommended 
comprising of AZT twice daily beginning from first trimester of pregnancy and at the onset of labour,  
single-dose of nevirapine and the first dose of a 7-day dual therapy (AZT+3TC) (Table 2.1.1)  [11]. 
Option B proposes that women not eligible for maternal life-long ART, should also receive ART from 
the first trimester, through childbirth until one week after cessation of breastfeeding or a week after 
delivery if not breastfeeding [11]. The requirement for monitoring disease progression through CD4 
count testing in options A and B, however, can be a disadvantage to HIV-positive women who have 
no ease of access to such services. The shift from one regimen to another also challenges monitoring 
and adherence in resource-limited settings. Drug resistance may pose a risk to women not on life-
long ART, who interrupt therapy between multiple pregnancies. Therefore, most recent guidelines 
(2013), which will be adopted nationally in South Africa in 2015, suggest a more aggressive but 
further simplified approach, Option B+, where all HIV positive mothers should take the daily triple 
therapy regardless of CD4 count levels for the rest of their lives in order to also protect future 









Table 2.1.1: WHO treatment and prophylaxis options to prevent vertical transmission of HIV during 
pregnancy and delivery. 
Regimen Option 
(WHO year) 
Treatment                         
(CD4 count ≤ 350cells/mm3 
Prophylaxis                       




(at lower CD4 
count cutoff of 
≤200cells/mm3) 
Triple therapy: daily, life-
long from diagnosis 
 
AZT: twice daily, from 
trimester2 
sd-NVP & first dose of 7-day 
AZT+3TC: at onset of labour 
2008* 
Option A (2010) Triple therapy: daily, life-
long from diagnosis 
AZT: twice daily, from first 
trimester 
sd-NVP & first dose of 7-day 
AZT+3TC: at onset of labour 
2010* 
Option B (2010) Triple therapy: daily, life-
long from diagnosis 
Triple therapy: daily, from 
first trimester & through 
delivery 
2013 
Option B+ (2012) Triple therapy: daily, life-
long from diagnosis 
Triple therapy: daily, life-long 
from diagnosis 
 
Treatment and prophylaxis options adapted from WHO reports 2010,[9,11]. #The CD4 cut-off given 
applies if woman has clinical disease stage 3 otherwise eligible if CD4 count ≤ 200 cells/mm3 or 
clinical disease is at stage 4[7]. *excludes 3TC from the regimen. 
  
2.2 Coverage, uptake and effectiveness of PMTCT regimens in sub-Saharan Africa   
In 2008, at least two detailed guidelines had already been published by the WHO that could 
effectively improve PMTCT programmes. Despite this, prophylaxis coverage was still below 50% while 
coverage for HIV testing was less than 30% in pregnant women from the sub-Saharan Africa [4]. 
Average effectiveness of ARVs used at the time in preventing MTCT, largely nevirapine-based 
regimens, was 50% in Africa [13]. The most widely used prophylactic regimen before 2010 in the 
continent was short-course AZT plus NVP during labour [14]. Despite these being very simple 
regimens, prophylaxis coverage in most remote-settings in Africa was still very low by 2010 with 
some countries only covering 50% of exposed infants with the simple nevirapine-based regimen [15]. 
Option A (Table 2.1.1) was then adopted in many parts of Africa since 2010 and it had a notable 




2.2.1 Challenges in PMTCT programs in sub-Saharan Africa 
Despite widespread attempts to reduce MTCT globally, most low-to-middle income countries in sub-
Saharan Africa have been slow in achieving the anticipated outcomes [16]. A number of factors are 
responsible. A major contributor has been the delay in making HIV testing routine for all pregnant 
women and it still is not in some settings [17]. Between 2007 and 2008 in Ivory Coast for example, 
only 60% of pregnant women were offered the opportunity to test for HIV of which 13% declined 
[18]. More problematic is poor coverage coupled with failure to adhere to treatment and ingestion of 
treatment is often not monitored, the focus being on the dispensing of drugs [19]. Coverage and 
adherence of the simplest regimen,  single dose NVP, at the onset of labour in some settings has 
been shown to be poor and as low as 24% [18]. Retention of HIV positive women in pre-ART follow-
up for appropriate timing of initiation of treatment has been shown to be a challenge [20–22]. A 
number of challenges also emanate from the health services perspective, and these include 
shortages of trained staff, incompetent administration, inadequate budgets and treatment stocks in 
clinics delaying initiation of therapy even to those who are loyal to the health services, [23–25][26]. 
Even though many of the countries in the region have achieved improved coverage after 2010, most 
of these problems remain a challenge in remote and rural settings [3]. 
 
2.3 PMTCT guidelines and implementation in South Africa 
Plans for a uniform approach for treating pediatric HIV in South Africa began in earnest within one 
province around year 2000 and led to the first strategy being published and implemented in 2004  
[27]. In 1999, the Western Cape province, through the Provincial Government, had the first PMTCT 
program at two clinics prior to any national policy on the issue of HIV treatment [28,29]. The results 
from a local clinic in the province proved the feasibility of implementing large-scale PMTCT services 
within routine urban clinic settings , the regimen comprising short-course AZT before delivery and 
NVP during labour and showing a MTCT rate of around 8-9% under a 22-26% exposure rate between 
1999 and 2003 [30]. This regimen was adopted in many health centers across the country until 
Option A was introduced in 2008 when the National Department of Health was expanding treatment 











Table 2.3: The South African treatment and prophylaxis regimens implemented to prevent vertical 
transmission of HIV during pregnancy and delivery. 
Year Treatment                                                    
(CD4 count ≤ 350cells/mm3) 
Prophylaxis                                              
(CD4 count >350cells/mm3) 
2001-2007# sd-NVP: at onset of labour  sd-NVP: at onset of labour 
2008-2010 HAART: daily, life-long from diagnosis AZT: trimester 2 
sd-NVP: at onset of labour 
2010-2013 HAART: daily, life-long from diagnosis sd-NVP & AZT(12 hourly): at onset of 
labour 
Treatment and prophylaxis options adapted from South Africa reports 2010 [31,32]. #The CD4 cutoff 
given applies if woman has clinical disease stage 3 otherwise eligible if CD4 count ≤ 200 cells/mm3 or 
clinical disease is at stage 4[7].  
 
2.3.1 HIV maternal prevalence and MTCT rate in South Africa since 2006 
The infant-exposure rate in South Africa reached a plateau in the past 4+ years with a national 
average around 30% [33].  The largest nation-wide MTCT survey was performed in 2010 and 
confirmed previous reports of wide differences between provinces, which causes concern and 
required a shift from focussing on the national average estimates alone [2,31]. The transmission rates 
are also variable across provinces. In 2010 for example, while the national MTCT rate was 3.5%, 
provincial rates ranged from 1.4% (in Northern Cape province) to 5.9% (in the Free State province) 
[31]. HIV testing and treatment/prophylaxis coverage were already above 96% and 80% in all 
provinces respectively yet provinces such as the Free State had the worst MTCT outcomes even 
though it did not have the highest local HIV exposure rate (31% compared to 44% in KwaZulu Natal, 
Figure 2.3.1) [31]. The case of the Free State province indicates an alarming problem around effective 
coverage. In Figure 2.3.1, we show the differences between provinces which had the highest and 
lowest MTCT rate or infant-exposure rate to illustrate that low maternal HIV prevalence does not 
necessarily guarantee reduced vertical transmission rates. The discrepancies between the rates of 







Figure 2.3.1: The 2010 HIV-infant exposure and vertical transmission rates in provinces with highest 
or lowest estimates and the national average [31] 
 
Within-province differences also exist between antenatal service clusters. A good example is the 
Western Cape province which had the earliest local PMTCT interventions in the country, where sub-
districts like Khayelitsha with long-standing antenatal services already achieved  transmission rates 
below 3% by 2010 yet the provincial average was 3.9% [29,31,34]. District-level differences are 
observed throughout the country’s provinces despite some having had received interventions at the 
same time [33].  
 
2.3.2 Challenges faced by South African PMTCT programs 
The challenges in South Africa faced around the PMTCT efforts are largely the same as the rest of 
sub-Saharan Africa. One most outstanding issue which has not been strongly taken into account is 
the socio-economic difference between provinces and districts which affects optimal usage of health 
care services. Some provinces, especially the Western Cape received successful interventions through 
well-structured antenatal clinics much earlier than other provinces [35] . Another common problem 
is about infected persons who have not reached critical clinical disease stages who generally do not 
visit health services ,thus making it difficult to keep track of their CD4 counts for accurately timing 
the initiating of therapy [18,33]. In pregnancy, testing coverage for HIV before delivery is high 
nationally. The 2010 routinely collected data reported a provincial coverage of at least 96% across the 
country but the challenge is in achieving early presentation, ideally during the first trimester, which 
impacts on vertical transmission [31,34,36,38]. Retention of those needing life-long therapy is also a 
challenge even in better resourced settings such as the well-established clinics in the Western Cape 
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Province [29,34]. Administrative discord, inadequate staffing and budget allocations in remote-
setting is a major contributor to poor patient care and should be addressed urgently [25,37].  
 
2.4 Incompetent systems for collecting and reporting health data 
Health systems for accurately collecting and storing routine data in health facilities remain sub-
optimal in many parts of sub-Saharan Africa including South Africa. Inconsistencies between data 
(HIV results or administered therapy) from clinic records and what is actually observed from cord-
blood tests confirm lack of competence in data collection systems [39]. Inaccuracy arises from 
different levels of the system, beginning with the initial visit to a health facility at which not all 
patients are captured into the system [40,41]. Incomplete capturing of all data elements required 
leading to a large proportion of missing data which reduces sample sizes for accurate research 
analyses is also common [42]. Errors, such as typographical errors in patient personal identifiers  and 
numerical figures,  in recording data are also common and can mislead routine reporting  and 
analyses [42].  Misdiagnosis of HIV leading to inappropriate treatment or delayed initiation of 
treatment is also an issue which needs to be dealt with urgently [43]. In many situations, 
incompetent and inadequately trained staff contribute to poor data collection and hence upgrading 
the data collection infrastructure will require simultaneous capacity building through staff training or 
employment of qualified and experienced personnel [41,44,45]. 
 
2.5 Conclusion: Eliminating the stagnant MTCT rates in South Africa 
South Africa is one of the countries in the sub-Saharan region that has made impressive progress 
towards PMTCT service effectiveness, but the MTCT rate remains above 2.5% on average. This is 
mainly because of health service issues in remote and poor settings where even recorded routine 
data are still inaccurate and unreliable [39]. Lessons need to be taken from such areas in the country 
by closely monitoring and assessing the implementation, delivery and uptake of PMTCT programs at 
district and facility levels. Systems strengthening approaches, shown to improve health program 
outcomes, are what the country needs to adopt at present so as to effectively address context-
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ABSTRACT (266 words) 
 
Single-dose nevirapine coverage and uptake in rural settings is an important indicator of the 
feasibility of implementing the more complex triple therapy regimens in routine prevention 
of mother-to-child HIV transmission services.  
 
A total of 1572 mother-infant pairs were included in a cross-sectional survey carried out in 
rural antenatal and delivery services from two districts in the Free State Province between 
2007 and 2008. HIV testing and nevirapine prophylaxis data were collected by nurses and 
compared to anonymously linked cord-blood tests which confirmed HIV status and ingestion 
of nevirapine. Logistic regression was used to assess variables from the clinic surveillance 
data: age, gravidity, mode of delivery, timing of HIV testing and number of antenatal visits 
during pregnancy, as predictors of adherence to nevirapine. 
 
Based on the Kappa statistic, clinic records under-estimated maternal HIV prevalence, 22% 
(95% CI 20-25) compared to 31% (95% CI 28-33) in cord-blood. In addition, cord-blood 
surveillance revealed that 19.6% of HIV-positive women given nevirapine according to the 
clinical records, did not ingest it (Kappa p-value<0.0001).  Women who attended at least 4 
antenatal visits were 4.7 times (95% CI 1.3-17.3, p-value=0.02) more likely to adhere than 




Uptake of all recommended antenatal cascade steps during pregnancy is important in 
improving adherence to a simple regimen such as single dose nevirapine.  Repeat testing of 
HIV until delivery is important to ensure optimal prophylaxis coverage. Interventions both at 
the service provider and user levels are required to ensure that data are accurately collected 
and to prevent and manage seroconversion during pregnancy as well as optimize the 




Nearly 50% of under-5 child deaths in South Africa are due to HIV infection through vertical 
transmission [1]. Although HIV incidence has declined among adults, HIV prevalence 
amongst pregnant women has stabilized at 30% due to a decrease in mortality as a result of 
the widespread roll out of ART.  There is therefore an imperative to focus on improving the 
effectiveness of services and programmes designed for the prevention of mother-to-child 
transmissions (PMTCT).  The need to balance feasibility of implementation of PMTCT 
programs, affordability and accessibility of treatment to all, has seen the South African 
government following the World Health Organization (WHO) PMTCT guidelines using 
cheaper drug options. The widely used regimen in the most recent years is Option A (life-
long triple therapy if CD4 count <350cells/mm3, otherwise dual prophylaxis starting with AZT 
and including single dose nevirapine (sd-NVP) at the onset of labour) [2]. Vertical 
transmission decreased  from at least 9% a decade ago to 3.5% in 2010 [2]. However, the 
complicated Option A regimen does not simplify implementation and could contribute to 
delayed complete elimination of mother-to-child transmission (MTCT). The shift between 
one form of treatment to another during pregnancy, delivery and breastfeeding, often in the 
context of a range of different service delivery complexities, makes it challenging to ensure 
optimal service delivery [3]. Although the most recently recommended PMTCT regimen 
options, Option B (triple therapy for all pregnant women and cessation of treatment at 6 
weeks post-delivery or one week after cessation of breast feeding) and Option B+ (life-long 
triple therapy for all HIV positive women - continued beyond child birth for life) [3], have not 
yet been widely adopted, the country has still made good progress, largely attributed to the 




Despite this progress towards eliminating MTCT in South Africa, exposure and transmission 
rates vary widely. In 2010, MTCT rates ranged from 1.4% in the Northern Cape Province to 
5.9% in the Free State province with exposure ranging between 16% (Northern Cape) and 
44% (KwaZulu-Natal). The MTCT rate in the Free State province was the highest, and higher 
than the national average (3.5%) while the exposure rate (i.e., exposure to HIV positive 
mothers) was the same as the national average (30%) [2].  These outcomes reveal missed 
opportunities within the PMTCT programs in the Free State province. In addition, the roll-out 
of ARVs in the Free State failed to meet the demand. In 2007, coverage for all people living 
with HIV was only 25% despite roll-out across all districts in the province [4]. This was largely 
because the need was underestimated, resulting in patients waiting up-to 3 months to 
receive treatment, insufficient budget allocations, shortages of trained staff, poor 
administration, and the widely used vertical delivery approach which did not integrate ART 
programs into the routine public health facility systems and limited access [4–8]. Other 
factors that have contributed to the slow improvements in PMTCT outcomes in the country 
include young child-bearing age, poor uptake of the antenatal services during pregnancy, 
delayed HIV testing, social stigma and low staff-to-patient ratio [7,9–11]. 
 
Currently there is a need to closely assess individual antenatal services, particularly the 
health systems infrastructure and operations, and identify inter-provincial and inter-district 
differences in order to adopt more context-specific services. Although the most recent 
Option B and -B+ guidelines have been shown to achieve better MTCT outcomes and simpler 
than Option A, they are not likely to be effective if the provider and the user do not perform 
optimally [3,12].  Issues around adherence, follow-up, psycho-socio factors, trained and 
dedicated frontline service providers, adequate budgets and treatment supplies as well as 
competent data collection systems for monitoring and reporting coverage, need to be 
addressed urgently. Inefficient health system structures and poor data management not only 
prohibit good outcomes from even the simplest regimens but also report inaccurate results 
which can mislead future health policies [13].  
 
In this study we assessed data from two resource-limited districts in the Free State Province. 
We report on PMTCT coverage at district level, i.e., HIV testing and dispensing of prophylaxis 
to pregnant women before delivery.  The data were from 2007 to 2008 just before the 
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adoption of Option A, when sd-NVP was the regimen used for PMTCT. Discrepancies were 
identified between data routinely recorded by service providers at the antenatal clinics such 
as HIV test results and recorded nevirapine coverage and data from cord blood samples 
which confirm HIV status and ingestion of nevirapine. We also explore factors associated 
with coverage. Challenges learned from a simpler sd-NVP regimen give a good reflection on 
the state of the health systems and service delivery and hence the preparedness for 






A cross-sectional survey of clinic records and cord-blood surveillance data from the Free 
State Province of South Africa was performed.  The data were collected as part of the PMTCT 
Effectiveness in Africa: Research and Linkages to care (PEARL) Study which set out to assess 
the effectiveness of PMTCT programs in four African countries (1), which received ethics 
approval from the University of Cape Town Research Ethics Committee.  Briefly, in the PEARL 
study, posters and direct communication by clinic staff were used to inform women about 
the study and formal consent was waived, in order to limit performance bias related to the 
aims of the study, in particular the adherence to prophylaxis. Data were anonymously 
collected from clinic folders into clinic surveillance forms and assigned new study numbers in 
order to protect the privacy and confidentiality of the participants. Therefore the data were 
unlinked such that individual participants could not be traced from the information given in 
the clinic surveillance form.  Cord-blood was drawn after delivery from the discarded 
placenta and analyses of these unlinked data were done in external laboratories from the 
clinics.  
Table 1 presents variables which were available on the clinic surveillance form. The available 
PMTCT cascade information made it possible to assess HIV testing during pregnancy, 
maternal HIV prevalence and dispensing of prophylactic regimens. Cordblood tests were 
performed to confirm HIV status and adherence to nevirapine. Adherence to nevirapine is 
defined as the proportion of those who accepted NVP at the clinics and in addition to being 
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confirmed HIV-positive by cord-blood survey after delivery, had an HIV-positive cord-blood 
NVP test outcome (ingested NVP). 
 
Statistical analyses and software 
Descriptive analyses were performed using non-parametric methods wherever the data 
failed to resemble a Gaussian distribution. Logistic regression was performed to identify 
factors influencing adherence to nevirapine which was treated as a binary variable 
(nevirapine present Yes/No). Associations and potential interactions between variables were 
assessed prior to implementing the logistic regression model. Only the independent 
variables which showed significant crude associations with adherence to nevirapine were 
added to the multivariate model. Potential confounding by other associated factors was 
taken into account when building the multivariate model, using forward stepwise 





The crude data, collected between 2007 and 2008, comprised 1679 records from women 
delivering infants in one of the 10 clinics servicing antenatal healthcare in the Motheo and 
Thabo Mofutsanyane districts of the Free State Province.  The two districts were randomly 
selected from the total of five in the province and then clinics with the largest number of 
attendees within these districts were chosen. Of the 1679 women who delivered at the 
clinics, a total of 107 did not receive antenatal care before delivery and were excluded from 
the analyses. Therefore this study focussed on the 1572 women who attended ANC at least 
once during pregnancy and they all delivered at the same facility which provided them with 
antenatal care. There were no significant differences between any measurable variables 
between the two districts (Table 1).  
The median age was 24 years, (Interquartile range (IQR):20-29 years). Most of the women 
had 1-2 children ever born to them (~70%), about 17% had 3 children while the rest had at 
least 4.  A strong positive relationship existed between age and gravidity (chi-squared p-
value<0.0001). Older women tended to have more children ever born to them and younger 
women (97% of the under 20 year old group) having their first or second pregnancy.  
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Primigravid women attended antenatal care (ANC) significantly more frequently than 
women having at least their third pregnancy (chi-squared p-value=0.002). Although the 
majority of women (90%) had normal vaginal delivery overall, a comparison between the 
different age-groups indicated that young women (12-19 years old) had the highest vaginal 
delivery proportion whilst the oldest women (31 years and older) had the highest proportion 
of caesarean deliveries (p-value<0.0001). Caesarean deliveries also appeared to be 
associated with more frequent antenatal visits (p-value<0.0001). A total of 1165 women 
tested for HIV according to the clinic surveillance records (Table 1). Of these, 10% (119) had 
been tested before the current pregnancy and 13.4% of them reported their past results as 
HIV-positive. Testing before the current pregnancy was not associated with having been 
pregnant before. 
 
PMTCT clinic coverage at district level according to routine data 
PMTCT coverage with respect to HIV testing at the clinics was 74% (1165) among the 1572 
women who attended ANC. Routine data reported that HIV prevalence among women 
testing was 22.4% (261/1165). Of the 261 women who had a positive HIV test at the clinics, 
all of them were offered prophylaxis with 90% receiving single-dose nevirapine. The 
remaining 10% were already on HAART, AZT alone or a combination of AZT+NVP (Figure 1).  
 
HIV prevalence and adherence to nevirapine and discrepancies between clinic 
records and cord-blood surveillance 
A total of 1545 of the 1572 women were included in the cord-blood surveillance. The 
remainder (1.7%) were not tested because of either severe haemolysis during delivery, cord 
blood clotting or unavailability of specimen for unstated reasons. A total of 460 (29.8%) were 
found to be HIV positive.  Nevirapine was tested on 441 of these HIV positive cord-blood 
samples and was confirmed present in only 54.4% of them (Figure 1). 
The Kappa statistic was used to assess agreement between clinic records and cord blood 
survey. There were 1146 women who had a recorded HIV test result from both the clinic 
record and cord blood. The agreement for HIV results between the routine data and cord-
blood test was 90.14% with a significant kappa statistic of 0.75 (p<0.0001), indicating 
moderate to substantial agreement. Of the 261 women with HIV positive outcomes at the 
clinics, 3% (8/261) were negative by cord blood tests (also confirmed not having ingested 
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nevirapine) and 12% (105/885) of those assigned negative outcomes at the clinics had HIV-
positive cord-blood outcomes. This latter group may include late sero-converters. Overall, 
the prevalence of HIV in this sample of 1146 women was 31% based on cord-blood while the 
clinic records underestimated the prevalence at 22%. 
 
 The clinic reported that all HIV-positive women not already on triple therapy were offered 
nevirapine. Cord blood was tested for the presence of nevirapine on all 218 cord-blood 
samples from such women but 20% of them had no trace of nevirapine indicating that it was 
not ingested and that adherence was 80% (Figure 1). The Kappa statistics showed an 
agreement of 79.8% between the nevirapine dispensation clinic records and the cord-blood 
tests which, however, could be a result of chance (kappa statistic k=0) due to the clinic 
records assumption that all eligible mothers (i.e., HIV positive) offered nevirapine accepted 
and ingested it and that the records indicate that all eligible mothers with matched cord-
blood samples were offered nevirapine (100% coverage). 
 
Factors influencing adherence to Nevirapine 
Woman’s age, gravidity, number of ANC visits, mode of delivery and timing of first HIV test 
during pregnancy were assessed as possible predictors of adherence to nevirapine. Data 
were available for 216 women and 80.6 % (174/216) were adherent to nevirapine according 
to cord-blood. Bivariate analyses are shown in Table 2.  In multivariate analyses, the model 
with only the number of ANC visits gave the best fit to the data, having the lowest AIC of 
213.79 (Table 3).  Women who had at least four ANC visits were 4.7 times more likely to 
adhere to nevirapine compared to those who attended only once (p-value=0.02, 95% CI 
1.26-17.25).  The results for 2-3 visits also indicate a trend that the higher the number of 
ANC visits, the more likely it is for women to adhere to their single-dose nevirapine (p-












This study showed that antenatal HIV prevalence between 2007 and 2008 was high in the 
Free State, with 1 in 3 pregnant women being HIV-positive.  The uptake of HIV testing was 
not optimal, with at least 25% of women failing to test for HIV before child-birth. Cord blood 
surveillance showed that nevirapine coverage was low at 54.4%. Cord-blood testing is 
important to confirm true maternal HIV prevalence during intrapartum as well as actual 
coverage and ingestion of prophylaxis. There are a number of possible reasons for the low 
uptake of testing. This may have been due the opt-in approach to counselling and testing 
where consent was obtained prior to testing. In 2010, this model was changed nationally to 
routine HIV testing in pregnancy, which has subsequently seen higher coverage in antenatal 
services [14]. Psycho-social factors such as denial and stigma were common at the time and 
most likely to be the largest contributors to sub-optimal testing [11,15]. 
 
The clinics reported 3% false HIV-positive results. Although records indicated these were 
offered nevirapine, cord blood tests confirmed that prophylaxis was not ingested. There are 
two main implications of this result. If these were not data capturing errors, giving false HIV-
positive results can cause unnecessary psychological trauma to the recipients. They were 
most likely recording errors, which raises concern about the quality and reliability of data 
from health facilities.  The 12% of women who were HIV-negative at ANC visit but confirmed 
HIV-positive at delivery could include late seroconverters who also contributed to the poor 
overall prophylaxis coverage observed here and in previous studies [16]. Our findings 
highlight the need to perform further HIV tests closer to delivery, or upon presentation in 
labour, to ensure that prophylaxis coverage is complete. While testing women of unknown 
status, or negative women in successive antenatal visits, or at 32 weeks gestation is a current 
guideline, it is unclear whether this is being fully implemented.  
 
Data collection at primary health care services in South Africa, like other African countries, is 
still a challenge and requires major focus as inaccurate estimation of coverage, for example 
an 8% under-estimation of HIV prevalence in this dataset, can mislead policy strategies 
[13,17]. Erroneous data has been reported in a number of local PMTCT evaluation studies 
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and data error includes false-positive HIV results, data inaccuracy and missing information 
mainly due to inadequately trained staff [18–20].  Standardized methods for measuring 
programme effectiveness are crucial as confidence in current reported data is discouraged 
by the poor quality data. Cord-blood tests are not practically feasible as part of daily testing 
mechanisms in normal routine settings. It is therefore important to adequately train staff on 
accurate data collection, reporting and monitoring skills to ensure that the effectiveness of 
the Option B regimen which is currently being introduced is not compromised. 
 
According to the clinic surveillance records, coverage for nevirapine was complete at 100%, 
i.e., everyone who had an HIV-positive results and not already on ART was offered 
nevirapine. However, it is not possible to ascertain whether coverage was indeed 100% or 
there were data entry errors. Assuming that the data are largely correct, cord blood tests 
confirmed that up to 20% of HIV positive women who were offered nevirapine failed to 
adhere. One problem that may be challenging to solve is the expected self-administration of 
nevirapine during labour. Although a single dose in itself is easier, labour is not a comfortable 
time to ascertain adherence on everyone. Service staff may need to encourage intake and 
ensure directly observed administration. Privacy should also be ensured as past reports have 
pointed out that stigma and fear of disclosure were some of the reasons for non-adherence 
[21,22]. This is particularly notable in the context of Option B, where ART is self-
administered. Hence directly observed therapy could be part of the routine procedures so as 
enhance optimal uptake as well as give accurate records of prophylaxis ingestion.  
 
There was lack of strong evidence for an association between adherence to prophylaxis with 
woman’s age, gravidity, mode of delivery and timing of first HIV test. Although a previous 
study reported an association between age and general uptake of antenatal services, we did 
not find a specific relationship to nevirapine intake [9].  Although, we found mode of 
delivery and gravidity to be associated with the number of ANC visits, the two factors did not 
independently determine adherence outcomes. Caesarean deliveries were not common but 
were associated with older age and more frequent antenatal visits likely indicating need-




Lack of maternal HIV testing is also a major determinant of PMTCT outcomes, hence we 
assessed whether women who self-initiated HIV testing prior to being pregnant would have 
had better outcomes than those who did not [10].  Similar to a previous study carried out in 
Africa, we found that the more frequent pregnant women visited the clinics antenatally, the 
better was the adherence to prophylaxis [17]. Therefore trust in the antenatal services needs 
to be encouraged in order to enhance optimal uptake of the PMTCT cascade and improve 
intervention outcomes.  Cellphone technology intervention  is one method which can be 
used to motivate and educate mothers along the PMTCT cascade via SMSs [23]. Negative 
psycho-social perceptions around HIV can be addressed through educating communities and 
mothers while also offering home-based follow-up counselling support for pregnant women 
to improve uptake and adherence [24,25]. Targeted psycho-social support offered within the 
clinic facilities through lay health workers has also improved uptake of the health services 
[26,27] 
 
There are several limitations to this study. Data entry errors cannot be completely ruled out 
in some of the cascade records from routine data capturing. For instance, the subset of 
women who were recorded as HIV-positive in the clinic surveillance records but contrary 
confirmed negative in cord blood are likely to be a result of errors in data capturing by 
service staff.  The cord-blood tests only confirmed nevirapine ingestion but adherence to 
ART on the remaining 10% of the participants was not carried out. Furthermore, women may 
have presented late in delivery and ingested NVP too late for it to reflect in the cord- blood, 
hence possibly underestimating the coverage. However, NVP is known to cross the placenta 
rapidly [9]. 
 
It has to be noted that the results are not generalizable across the entire Free State province 
because these data relate to non-urban settings. Also the data are from 2007-2008 and the 
PMTCT regimen has since changed. However, lessons from uptake, adherence and service 
operations still remain valid and are generalizable across other resource-limited settings in 
the country. Further studies will still need to be carried out to assess service provision and 
uptake in the case of home-based births, which were not available in this dataset, but are 







In conclusion, evidence from this study confirms the need for more frequent use of 
antenatal services, hence measures need to be put in place to attract pregnant women to 
have trust and loyalty to these services. Frequent visits will allow for time to educate 
mothers about the importance of PMTCT and hence improve adherence which from this 
study is an evident problem. In particular, women need messages from the health service 
that encourage early first-time visits during the first trimester. Current evidence reports  that 
less than half of pregnant women have their first visits before 20 weeks of gestation yet 
most recent guidelines further require much earlier initiation of therapy to eliminate MTCT 
[28,29]. Hindrances to visiting the clinic more often, such as transport, unplanned 
pregnancies and fear of disclosure, employment commitments and ease of access to facility, 
need to be assessed with respect to each community and clinic settings. Although great 
improvements have taken place at the national level, the impact of lower-level differences 
should not be ignored if the complete elimination of MTCT is to be achieved. In the case of 
the more effective option B+ which is simpler than Options –A and –B but likely more 
demanding than sd-NVP, a context-specific approach (at district and facility level) still needs 
to be used to improve coverage, especially in resource-limited settings like the rural Free 
State Province, in order to achieve optimal delivery, uptake, adherence and effectiveness. If 
adherence was poor for a simple sd-NVP regimen, the reasons for that need to be identified 
and dealt with in order to avoid compromising the more effective new regimens. Given the 
scientific evidence supporting Option B+, resources and efforts need to target these guidelines, 
however, it I important to highlight the lessons learned from a simpler (less effective regimen), in 
order to optimise the new intervention. The health system structures should be tailored to 
meet the local demand and socio-economic setting. Operational structures should be made 
available and adequate. Adequate and trained staffing is necessary for all different sectors 
linked to the PMTCT cascade, with additional focus on data reporting in the context of 
programme monitoring and evaluation. The role of community health workers should also 
be expanded to cover community awareness programs, follow-up, counselling and 
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Figure 1: Summary of clinic records and cord-blood survey for mother-infant PMTCT data.  
The PMTCT cascade showing summary of women delivering at clinics (solid clear boxes), 
confirmation of clinic HIV result & NVP intake with cord blood tests (dashed clear boxes) and 
overall HIV prevalence & NVP intake from cord-blood tests (dashed grey boxes). 
*Possibility of late sero-conversion and not entirely an error in clinic tests/records 
 #those who actually ingested NVP i.e. level of adherence  
¥1.7% not tested in cord blood because either baby born before arrival at clinic, cord broke, 
stillbirth or forgot to take sample 
 
TABLES 
Table 1: PMTCT Cascade variables available in the clinic surveillance data 
 Motheo District Thabo M District P-value~ Total (IQR or 
%) 
All women with >=1 ANC visits 
Age in years#1 
     Median (IQ) 
     % Proportion (95% CI) 
     < 20 
     20 – 30 
     > 30  
Antenatal care visits 
     Median (IQ) 
    % Proportion (95% CI) 
     0 – 1 
     2 – 3 
     ≥ 4 
Gravidity#2 
     Median (IQ) 
     % Proportion (95% CI) 
     ˂ 3 
     3 
     ≥ 4 
Method of delivery#3 
     % Proportion (95% CI) 
     Vaginal 
     Ceasarian section 
 
HIV tested before delivery 
HIV positive  in clinic records  
     Offered NVP before delivery 

















































































































Thabo M = Thabo Mofutsanyane; ~Bivariate comparisons using Mann-Whitney test, chi-
squared test or Kruskal-Wallis test; #1Missing age information for 2 participants (1 from each 
district); #2Missing gravidity information for 2 participants from Matheo districts; #3Missing 
mode of delivery for 3 participants (1 in Motheo & 2 in Thabo M);  *Already on 




Table 2: Univariate analysis of predictors of adherence to nevirapine 
Variables Odds Ratio  P-value 
Age: >21 yrs compared to <=20 
yrs old 
1.2 0.56 
Gravidity: >=3 compared to <3 1.0 0.96 
ANC visits: 2-3 compared to 1 
visit 
4.3 0.04 
ANC visits: >=4 compared to 1 
visit 
4.7 0.02 
Mode of delivery: caesarian 
compared to vaginal  
1.6 0.47 
HIV test timing: during pregnancy 




Table 3:  Details of the best-fitting model 
Variable Odds Ratio P-values 95% CI 
ANC visits 2-3 vs 1  








1.04 ; 17.75 
1.26 ; 17.25 
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Footnotes can be used to explain abbreviations. Citations should be indicated using the same style 
as outlined above. Tables occupying more than one printed page should be avoided, if possible. 
Larger tables can be published as Supporting Information. Please ensure that table formatting 
conforms to our Guidelines for table preparation (or SEE 3 BELOW)..  
 
Figure Legends 
Figures should not be included in the manuscript file, but figure legends should be. Guidelines for 
preparing figures can be found here (or SEE 2 BELOW). 
Figure legends should describe the key messages of a figure. Legends should have a short title of 15 
words or less. The full legend should have a description of the figure and allow readers to 
understand the figure without referring to the text. The legend itself should be succinct, avoid 
lengthy descriptions of methods, and define all non-standard symbols and abbreviations.  
1. Policies 
Copyright and the Open Access Licenses 
The Copyright and License Policies that apply to articles also apply to figures. Please do not submit any 
figures, photos, or tables that have been previously copyrighted unless you have and can supply written 
permission from the copyright holder to publish under the CC-BY or CC0 license. Without this, we cannot 
publish the figures. 
Image Manipulation 
Submitted image files should not be manipulated or adjusted in any way that could lead to misinterpretation 
of the information present in the original image. Inappropriate manipulation includes, but is not limited to: 
• The introduction, enhancement, movement, or removal of specific feature(s) within an image 
• Unmarked grouping of images that should otherwise have been presented separately (for 
example, from different parts of the same gel, or from different gels, fields, or exposures) 
• Adjustments of brightness, contrast, or color balance that obscure, eliminate, or misrepresent any 
information 
Digital images in manuscripts nearing acceptance for publication may be scrutinized for any indication of 
improper manipulation. If evidence is found of inappropriate manipulation, we reserve the right to ask for 
original data and, if that is not satisfactory, we may decide not to accept the manuscript and may also 
contact the authors' institutions to ask them to assist with investigation. 
Depictions of Humans 
For papers that include identifying, or potentially identifying, information, authors must download the 
Consent Form for Publication in a PLOS Journal (PDF), which the individual, parent, or guardian must sign 
once they have read the paper and been informed about the terms of PLOS open-access license. The 
signed consent form should not be submitted with the manuscript, but authors should securely file it in the 
individual's case notes, and the methods section of the manuscript should explicitly state that consent 
authorization for publication is on file, using wording like: “The individual in this manuscript has given 
written informed consent (as outlined in PLOS consent form) to publish these case details.” Examples of 
such identifying information include, but are not limited to: photographs, radiographs, pedigrees (family 
trees), and geospatial maps that can identify a specific location such as a house. If you require further 




PLOS can accept only TIFF or EPS for publication. Figures should be uploaded separately, not embedded 
in the article file. See the table below for a summary of requirements. The following applies only to graphics 
published directly as figures within articles. Supporting Information figures have fewer requirements. 
For detailed information, see our complete Figure Specifications. Figure Instructions contains more 
information on creating, modifying, or combining figures to comply with the specifications. 
Figure Requirements in Brief 
All figures Dimensions Maximum: 17.35 cm W x 23.35 cm H  
Minimum: 8.3 cm W 
 Column fitting Sized to fit columns in the final printed PDF 
 Color mode RGB (8 bit/channel) or grayscale only 
 Within-figure text Arial, Times, or Symbol 8-12 point 
 Number/title/caption/image credit Number/title/caption/image credit 
 Lines/rules/strokes Minimum 0.5 point 
 Multi-panel figures Figure file must contain all parts in one file 
 White space Crop out excess from around image content 
 File size Under 10 MB 
 Orientation Vertical, not turned sideways 
TIFF Resolution 300-600 ppi 
 Layers Flattened, no layers 
 Alpha channels No alpha channels 
 Compression LZW required 
 Background color White, not transparent 
EPS Text Must be converted to outlines or saved with 
embedded fonts 
 CS5 Save as CS4-compatible 
Multimedia PLOS cannot directly publish multimedia files in articles, but encourages their submission as 
Supporting Information. 
3. Tables 
The following applies only to tables published directly within articles. Tables submitted as Supporting 
Information have fewer requirements. Tables submitted for direct publication should be included at the very 
end of the article file, not submitted as separate files. 
For detailed information, see our complete Table Specifications. 
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Table Requirements in Brief 
Layout Tables must be primarily cell-based and fully editable. 
Structuring the 
table 
Do not use the following to organize data or structure the table:  
 Returns (“Enter” key) 
 Tabs 
 Spaces 
 Colored text 
 Cell shading 
 Cells within cells 
Software Word (preferred), Excel, LaTeX 
Graphics No graphics, boxes, or embedded tables. 
Dimensions Very large tables are acceptable, but may be set vertically and/or span several pages in 
the final PDF. 
Text Colored fonts will not appear in published version; use bold or italic for emphasis. 
Parts No parts. Make Table 1A and Table 1B into Tables 1 and 2, or combine into one table. 
4. Supporting Information 
Supporting Information is not published directly in the article; rather, a link to the file is provided in the 
online version of the published article. The information contained in these files is ancillary to the article's 
content, although occasionally important data are included if the file size is excessive or the file type is not 
supported in the main article. 
For more detailed information, see our complete Supporting Information Guidelines. 
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